DexCom (NASDAQ:DXCM) Reaches New 1-Year Low – Time to Sell?

DexCom, Inc. (NASDAQ:DXCM) shares reached a new 52-week low on Thursday . The stock traded as low as $61.74 and last traded at $62.24, with a volume of 1724552 shares. The stock had previously closed at $68.14.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DXCM. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Stock Down 3.2 %

The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $23.38 billion, a PE ratio of 41.84, a P/E/G ratio of 2.30 and a beta of 1.28. The stock’s fifty day simple moving average is $80.14 and its 200-day simple moving average is $76.87.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Several institutional investors have recently added to or reduced their stakes in the business. Watts Gwilliam & Co. LLC bought a new stake in shares of DexCom in the fourth quarter valued at approximately $3,334,000. Congress Asset Management Co. raised its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after acquiring an additional 222,548 shares in the last quarter. First Hawaiian Bank boosted its holdings in shares of DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock worth $1,801,000 after acquiring an additional 19,629 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. grew its position in shares of DexCom by 500.0% in the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical device company’s stock valued at $467,000 after purchasing an additional 5,000 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.